These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 19930004

  • 1. Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting.
    Brixner DI, McAdam-Marx C, Ye X, Boye KS, Nielsen LL, Wintle M, Misurski D, Fabunmi R.
    Diabetes Obes Metab; 2009 Dec; 11(12):1122-30. PubMed ID: 19930004
    [Abstract] [Full Text] [Related]

  • 2. Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting.
    Pawaskar M, Li Q, Hoogwerf BJ, Reynolds MW, Faries D, Engelman W, Bruhn D, Bergenstal RM.
    Diabetes Obes Metab; 2012 Jul; 14(7):626-33. PubMed ID: 22321776
    [Abstract] [Full Text] [Related]

  • 3. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
    Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM.
    Diabetes Obes Metab; 2006 Jul; 8(4):436-47. PubMed ID: 16776751
    [Abstract] [Full Text] [Related]

  • 4. Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States.
    Pawaskar M, Li Q, Hoogwerf BJ, Reynolds MW, Lee LJ, Fonseca V.
    Endocr Pract; 2012 Jul; 18(5):700-11. PubMed ID: 22982784
    [Abstract] [Full Text] [Related]

  • 5. Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.
    Bergenstal RM, Li Y, Porter TK, Weaver C, Han J.
    Diabetes Obes Metab; 2013 Mar; 15(3):264-71. PubMed ID: 23078638
    [Abstract] [Full Text] [Related]

  • 6. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.
    Grimm M, Han J, Weaver C, Griffin P, Schulteis CT, Dong H, Malloy J.
    Postgrad Med; 2013 May; 125(3):47-57. PubMed ID: 23748506
    [Abstract] [Full Text] [Related]

  • 7. Real-world clinical outcomes and predictors of glycaemic and weight response to exenatide once weekly in patients with type 2 diabetes: The CIBELES project.
    Gorgojo-Martínez JJ, Gargallo-Fernández MA, Brito-Sanfiel M, Lisbona-Catalán A.
    Int J Clin Pract; 2018 Mar; 72(3):e13055. PubMed ID: 29341370
    [Abstract] [Full Text] [Related]

  • 8. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
    Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG.
    Curr Med Res Opin; 2008 Jan; 24(1):275-86. PubMed ID: 18053320
    [Abstract] [Full Text] [Related]

  • 9. The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review.
    Best JH, Lavillotti K, DeYoung MB, Garrison LP.
    Diabetes Obes Metab; 2012 May; 14(5):387-98. PubMed ID: 22074017
    [Abstract] [Full Text] [Related]

  • 10. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting.
    Yoon NM, Cavaghan MK, Brunelle RL, Roach P.
    Clin Ther; 2009 Jul; 31(7):1511-23. PubMed ID: 19695400
    [Abstract] [Full Text] [Related]

  • 11. A1C and weight outcomes at 18 months in patients with type 2 diabetes treated with exenatide in an ambulatory care setting.
    McAdam-Marx C, Ye X, Brixner DI, Fabunmi R, Wintle M, Boye KS, Misurski D, Nielsen LL.
    Diabetes Obes Metab; 2009 Dec; 11(12):1173-4. PubMed ID: 19930007
    [No Abstract] [Full Text] [Related]

  • 12. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
    Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, GWAA Study Group.
    Ann Intern Med; 2005 Oct 18; 143(8):559-69. PubMed ID: 16230722
    [Abstract] [Full Text] [Related]

  • 13. Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting.
    Pawaskar M, Li Q, Reynolds MW.
    Curr Med Res Opin; 2012 Jun 18; 28(6):991-7. PubMed ID: 22519390
    [Abstract] [Full Text] [Related]

  • 14. Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting.
    Bhushan R, Elkind-Hirsch KE, Bhushan M, Butler WJ, Duncan K, Marrioneaux O.
    Diabetes Technol Ther; 2009 Jun 18; 11(6):353-9. PubMed ID: 19459763
    [Abstract] [Full Text] [Related]

  • 15. [Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].
    Pujante Alarcón P, Hellín Gil MD, Román LM, Ferrer Gómez M, García Zafra MV, Tébar Massó J.
    Med Clin (Barc); 2012 Dec 01; 139(13):572-8. PubMed ID: 22209597
    [Abstract] [Full Text] [Related]

  • 16. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, Ni Y, Liu D, Zhu Z.
    Diabetes Obes Metab; 2013 Aug 01; 15(8):737-49. PubMed ID: 23433305
    [Abstract] [Full Text] [Related]

  • 17. Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.
    Zhang Q, Rajagopalan S, Mavros P, Engel SS, Davies MJ, Yin D, Radican L.
    Adv Ther; 2010 Apr 01; 27(4):223-32. PubMed ID: 20464538
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
    Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.
    Clin Ther; 2008 Aug 01; 30(8):1448-60. PubMed ID: 18803987
    [Abstract] [Full Text] [Related]

  • 19. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.
    Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, Zhang B, Bicsak TA, Brodows RG, Kim DD.
    Diabetes Obes Metab; 2006 Jul 01; 8(4):419-28. PubMed ID: 16776749
    [Abstract] [Full Text] [Related]

  • 20. Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide*.
    Paul S, Best J, Klein K, Han J, Maggs D.
    Diabetes Obes Metab; 2012 Sep 01; 14(9):826-34. PubMed ID: 22510305
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.